NCT02292615UnknownNot Applicable
Application of Integrated MR-PET in Patients With Gynecologic Cancers
National Taiwan University Hospital1 site in 1 country220 target enrollmentStarted: April 2014Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 220
- Locations
- 1
- Primary Endpoint
- The imaging biomarkers determined by MR-PET
Study Overview
Brief Summary
In this prospective cohort study, patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers) and patients with suspicious recurrent gynecologic cancers will be enrolled. The study period is two years and the estimated patient number is about 220. Patients will undergo image study before and after treatment. The diagnostic accuracy of MR-PET in cancer staging and the potential image biomarkers to monitor treatment response and predict treatment outcome will be investigated.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 20 Years to 90 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers).
- •Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers).
- •Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy.
Exclusion Criteria
- •Age <20 or >90 years old
- •Contraindication for MRI:
- •Contraindication for MR contrast medium (Cre > 2.0)
- •History of other malignancy
- •Prior arthroplasty of hip or pelvic bone surgery with metallic fixation (may cause artifacts on MRI)
- •Pregnant or lactating women
Outcomes
Primary Outcomes
The imaging biomarkers determined by MR-PET
Time Frame: 3 months
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Hybrid PET/MR in the Therapy of Cervical CancerCervix CarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell CarcinomaNCT01759355UNC Lineberger Comprehensive Cancer Center18
Active, not recruiting
Early Phase 1
PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical CancerStage IA Cervical CancerStage IA1 Cervical CancerStage IA2 Cervical CancerStage IB Cervical CancerStage IB1 Cervical CancerStage IB2 Cervical CancerStage IB3 Cervical CancerNCT04219904M.D. Anderson Cancer Center25
Suspended
Not Applicable
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.Pet-ctProstate CancerNCT06355843The First Affiliated Hospital of Anhui Medical University50
Recruiting
Phase 1
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid LeukemiaAcute Myeloid LeukemiaAcute Promyelocytic Leukemia With PML-RARANCT02390635M.D. Anderson Cancer Center77
Unknown
Not Applicable
Application of MR-PET in Colorectal CancerColorectal CancerNCT02553031National Taiwan University Hospital100